Academic Radiology
Volume 17, Issue 9 , Pages 1175-1185 , September 2010

Measuring the “Unmeasurable” Assessment of Bone Marrow Response to Therapy Using FDG-PET in Patients with Lymphoma

  • Behnaz Goudarzi, MD

      Affiliations

    • Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, 601 North Caroline Street, JHOC 3223, Baltimore, MD 21287-0817
    • ,
  • Heather A. Jacene, MD

      Affiliations

    • Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, 601 North Caroline Street, JHOC 3223, Baltimore, MD 21287-0817
    • ,
  • Richard L. Wahl, MD

      Affiliations

    • Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, 601 North Caroline Street, JHOC 3223, Baltimore, MD 21287-0817
    • Corresponding Author InformationAddress correspondence to: R.L.W.

Received 18 February 2010 ,Accepted 1 May 2010.

References 

  1. Coller BS, Chabner BA, Gralnick HR. Frequencies and patterns of bone marrow involvement in non-Hodgkin's lymphomas: observations on the value of bilateral biopsies. Am J Hematol. 1977;3:105–119
  2. Bitran JD, Golomb HM, Ultmann JE, et al. Non-Hodgkin's lymphoma, poorly differentiated lymphocytic and mixed cell types: results of sequential staging procedures, response to therapy, and survival of 100 patients. Cancer. 1978;42:88–95
  3. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  4. Tatsumi M, Cohade C, Nakamoto Y, et al. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology. 2005;237:1038–1045
  5. Nakamoto Y, Cohade C, Tatsumi M, et al. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology. 2005;237:627–634
  6. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340–3346
  7. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005;46:958–963
  8. Park YH, Kim S, Choi SJ, et al. Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone. Ann Oncol. 2005;16:1401–1402
  9. Park YH, Choi SJ, Ryoo BY, Kim HT. PET imaging with F-18 fluorodeoxyglucose for primary lymphoma of bone. Clin Nucl Med. 2005;30:131–134
  10. Moog F, Bangerter M, Diederichs C, et al. Extranodal malignant lymphoma: detection with F-l8-FDG PET versus CT. Radiology. 1998;206:475–481
  11. Moog F, Bangerter M, KotzerkeI , et al. FDG PET as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16:603–609
  12. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875–3876
  13. Muslimani AA, Faraq HL, Francis S, et al. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma. Am J Clin Oncol. 2008;31:409–412
  14. Pelosi E, Pregno P, Penna D, et al. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med. 2008;113:578–590
  15. Pelosi E, Penna D, Deandreis D, et al. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging. 2008;52:9–16
  16. Schaefer NG, Strobel K, Taverna C, et al. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2007;34:60–67
  17. Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18:1685–1690
  18. Salaun PY, Gastinne T, Bodet-Milin C, et al. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?. Eur J Nucl Med Mol Imaging. 2009;36:1813–1821
  19. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244–1253
  20. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586
  21. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–578
  22. Sugawara Y, Fisher SJ, Zasadny KR, et al. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 1998;16:173–180
  23. Jacene HA, Ishimori T, Engles JM, et al. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med. 2006;47:950–956
  24. Blodgett TM, Ames JT, Torok FS, et al. Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin. Clin Nucl Med. 2004;29:161–163
  25. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247
  26. Wahl RL, Jacene H, Lodge MA. From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S
  27. Freudenberg LS, Antoch G, Schütt P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325–329
  28. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 2001;115:793–800
  29. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large b-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626–1632
  30. Murata Y, Kubota K, Yukihiro M, et al. Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT. Nucl Med Biol. 2006;33:999–1004
  31. Nahmias C, Hanna WT, Wahl LM, et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med. 2007;48:744–751
  32. Kazama T, Swanston N, Podoloff DA, et al. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging. 2005;32:1406–1411
  33. Lin EC. FDG PET/CT flip flop phenomenon in treated lymphoma of bone. Clin Nucl Med. 2006;31:803–805
  34. Shammas A, Lim R, Charron M. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions. Radiographics. 2009;29:1467–1486
  35. Mahmood S, Llano M. Paget disease of the humerus mimicking metastatic disease in a patient with metastatic malignant mesothelioma on whole body F-18 FDG PET/CT. Clin Nucl Med. 2008;33:510–512
  36. Bybel B. F-18 FDG PET/CT following dental extraction in a patient with head and neck cancer. Clin Nucl Med. 2007;32:741–742
  37. Shin D, Shon O, Han D, et al. The clinical efficacy of 18F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Ann Nucl Med. 2008;22:603–609
  38. Aoki J, Endo K, Watanabe H, et al. FDG-PET for evaluating musculoskeletal tumors. J Orthop Sci. 2003;8:435–441
  39. Feldman F, Heertum RV, Manos C. 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol. 2003;32:201–208
  40. Mester U, Even-Sapir E. Increased 18F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med. 2007;37:206–222
  41. Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, et al. The role of quantitative 18F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med. 2002;43:510–518
  42. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology. 2001;219:774–777
  43. Grigolon MV, Delbeke D. F-18FDG uptake in a bone infarct: a case report. Clin Nucl Med 2001; 26:613–614.
  44. Rosen R, Fayad L, Wahl RL. Increased 18F-FDG uptake in degenerative disease of the spine: characterization with 18F-FDG PET/CT. J Nucl Med. 2006;47:1274–1280
  45. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–994
  46. Schein P, Chabner B, Canellos G, et al. Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy. Cancer. 1975;35:354–357
  47. Wirth A, Corry J, Laidlaw C, et al. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. Int J Radiation Oncology Biol Phys. 1997;39:599–607

 Supported in part by a grant from NIH/NCI (3 P30 CA006973-43S2 Abeloff/Wahl for IRAT: Imaging Response Assessment Teams in Cancer Center Supplement).

PII: S1076-6332(10)00253-9

doi: 10.1016/j.acra.2010.05.001

Academic Radiology
Volume 17, Issue 9 , Pages 1175-1185 , September 2010

Article Tools

* Image Usage & Resolution